331 related articles for article (PubMed ID: 24049136)
1. Natalizumab affects the T-cell receptor repertoire in patients with multiple sclerosis.
Warnke C; Mausberg AK; Stettner M; Dehmel T; Nekrich L; Meyer zu Horste G; Hartung HP; Fogdell-Hahn A; Adams O; Kieseier BC
Neurology; 2013 Oct; 81(16):1400-8. PubMed ID: 24049136
[TBL] [Abstract][Full Text] [Related]
2. Update on PML and PML-IRIS occurring in multiple sclerosis patients treated with natalizumab.
Kleinschmidt-DeMasters BK; Miravalle A; Schowinsky J; Corboy J; Vollmer T
J Neuropathol Exp Neurol; 2012 Jul; 71(7):604-17. PubMed ID: 22710964
[TBL] [Abstract][Full Text] [Related]
3. Risk of natalizumab-associated progressive multifocal leukoencephalopathy.
Bloomgren G; Richman S; Hotermans C; Subramanyam M; Goelz S; Natarajan A; Lee S; Plavina T; Scanlon JV; Sandrock A; Bozic C
N Engl J Med; 2012 May; 366(20):1870-80. PubMed ID: 22591293
[TBL] [Abstract][Full Text] [Related]
4. The effect of plasma exchange on serum anti-JC virus antibodies.
Subramanyam M; Plavina T; Khatri BO; Fox RJ; Goelz SE
Mult Scler; 2013 Jun; 19(7):912-9. PubMed ID: 23232602
[TBL] [Abstract][Full Text] [Related]
5. Immunological and clinical consequences of treating a patient with natalizumab.
Schwab N; Höhn KG; Schneider-Hohendorf T; Metz I; Stenner MP; Jilek S; Du Pasquier RA; Gold R; Meuth SG; Ransohoff RM; Brück W; Wiendl H
Mult Scler; 2012 Mar; 18(3):335-44. PubMed ID: 21908480
[TBL] [Abstract][Full Text] [Related]
6. Immune-reconstitution Inflammatory Syndrome in Multiple Sclerosis Patients Treated With Natalizumab: A Series of 4 Cases.
N'gbo N'gbo Ikazabo R; Mostosi C; Quivron B; Delberghe X; El Hafsi K; Lysandropoulos AP
Clin Ther; 2016 Mar; 38(3):670-5. PubMed ID: 26856928
[TBL] [Abstract][Full Text] [Related]
7. Clinically silent PML and prolonged immune reconstitution inflammatory syndrome in a patient with multiple sclerosis treated with natalizumab.
Blinkenberg M; Sellebjerg F; Leffers AM; Madsen CG; Sørensen PS
Mult Scler; 2013 Aug; 19(9):1226-9. PubMed ID: 23508652
[TBL] [Abstract][Full Text] [Related]
8. The chameleon of neuroinflammation: magnetic resonance imaging characteristics of natalizumab-associated progressive multifocal leukoencephalopathy.
Wattjes MP; Richert ND; Killestein J; de Vos M; Sanchez E; Snaebjornsson P; Cadavid D; Barkhof F
Mult Scler; 2013 Dec; 19(14):1826-40. PubMed ID: 24192217
[TBL] [Abstract][Full Text] [Related]
9. L-selectin is a possible biomarker for individual PML risk in natalizumab-treated MS patients.
Schwab N; Schneider-Hohendorf T; Posevitz V; Breuer J; Göbel K; Windhagen S; Brochet B; Vermersch P; Lebrun-Frenay C; Posevitz-Fejfár A; Capra R; Imberti L; Straeten V; Haas J; Wildemann B; Havla J; Kümpfel T; Meinl I; Niessen K; Goelz S; Kleinschnitz C; Warnke C; Buck D; Gold R; Kieseier BC; Meuth SG; Foley J; Chan A; Brassat D; Wiendl H
Neurology; 2013 Sep; 81(10):865-71. PubMed ID: 23925765
[TBL] [Abstract][Full Text] [Related]
10. Punctate lesion pattern suggestive of perivascular inflammation in acute natalizumab-associated progressive multifocal leukoencephalopathy: productive JC virus infection or preclinical PML-IRIS manifestation?
Wattjes MP; Verhoeff L; Zentjens W; Killestein J; van Munster ET; Barkhof F; van Eijk JJ
J Neurol Neurosurg Psychiatry; 2013 Oct; 84(10):1176-7. PubMed ID: 23695498
[No Abstract] [Full Text] [Related]
11. Simultaneous PML-IRIS after discontinuation of natalizumab in a patient with MS.
Gheuens S; Smith DR; Wang X; Alsop DC; Lenkinski RE; Koralnik IJ
Neurology; 2012 May; 78(18):1390-3. PubMed ID: 22517104
[TBL] [Abstract][Full Text] [Related]
12. Disease course and outcome of 15 monocentrically treated natalizumab-associated progressive multifocal leukoencephalopathy patients.
Dahlhaus S; Hoepner R; Chan A; Kleiter I; Adams O; Lukas C; Hellwig K; Gold R
J Neurol Neurosurg Psychiatry; 2013 Oct; 84(10):1068-74. PubMed ID: 23606731
[TBL] [Abstract][Full Text] [Related]
13. Progressive multifocal leukoencephalopathy after natalizumab discontinuation.
Fine AJ; Sorbello A; Kortepeter C; Scarazzini L
Ann Neurol; 2014 Jan; 75(1):108-15. PubMed ID: 24242357
[TBL] [Abstract][Full Text] [Related]
14. [Progressive multifocal leukoencephalopathy as a complication of natalizumab therapy].
Soilu-Hänninen M; Päivärinta M; Sonninen P; Parkkola R; Vuorinen T; Erälinna JP
Duodecim; 2013; 129(7):765-70. PubMed ID: 23720945
[TBL] [Abstract][Full Text] [Related]
15. Surgical management of malignant cerebral edema secondary to immune reconstitution inflammatory syndrome from natalizumab-associated progressive multifocal encephalopathy.
Tan LA; Lopes DK
J Clin Neurosci; 2015 Oct; 22(10):1669-71. PubMed ID: 26115897
[TBL] [Abstract][Full Text] [Related]
16. Lipid-specific immunoglobulin M bands in cerebrospinal fluid are associated with a reduced risk of developing progressive multifocal leukoencephalopathy during treatment with natalizumab.
Villar LM; Costa-Frossard L; Masterman T; Fernandez O; Montalban X; Casanova B; Izquierdo G; Coret F; Tumani H; Saiz A; Arroyo R; Fink K; Leyva L; Espejo C; Simó-Castelló M; García-Sánchez MI; Lauda F; Llufriú S; Álvarez-Lafuente R; Olascoaga J; Prada A; Oterino A; de Andrés C; Tintoré M; Ramió-Torrentà L; Rodríguez-Martín E; Picón C; Comabella M; Quintana E; Agüera E; Díaz S; Fernandez-Bolaños R; García-Merino JA; Landete L; Menéndez-González M; Navarro L; Pérez D; Sánchez-López F; Serrano-Castro PJ; Tuñón A; Espiño M; Muriel A; Bar-Or A; Álvarez-Cermeño JC
Ann Neurol; 2015 Mar; 77(3):447-57. PubMed ID: 25581547
[TBL] [Abstract][Full Text] [Related]
17. Pathology of immune reconstitution inflammatory syndrome in multiple sclerosis with natalizumab-associated progressive multifocal leukoencephalopathy.
Metz I; Radue EW; Oterino A; Kümpfel T; Wiendl H; Schippling S; Kuhle J; Sahraian MA; Gray F; Jakl V; Häusler D; Brück W
Acta Neuropathol; 2012 Feb; 123(2):235-45. PubMed ID: 22057786
[TBL] [Abstract][Full Text] [Related]
18. Immune reconstitution inflammatory syndrome in natalizumab-associated PML.
Tan IL; McArthur JC; Clifford DB; Major EO; Nath A
Neurology; 2011 Sep; 77(11):1061-7. PubMed ID: 21832229
[TBL] [Abstract][Full Text] [Related]
19. Blood miRNA expression pattern is a possible risk marker for natalizumab-associated progressive multifocal leukoencephalopathy in multiple sclerosis patients.
Muñoz-Culla M; Irizar H; Castillo-Triviño T; Sáenz-Cuesta M; Sepúlveda L; Lopetegi I; López de Munain A; Olascoaga J; Baranzini SE; Otaegui D
Mult Scler; 2014 Dec; 20(14):1851-9. PubMed ID: 24852919
[TBL] [Abstract][Full Text] [Related]
20. Presumptive progressive multifocal leukoencephalopathy in multiple sclerosis after natalizumab therapy.
Eisele P; Szabo K; Hornberger E; Griebe M; Hennerici MG; Kieseier BC; Gass A
J Neuroimaging; 2014; 24(4):425-8. PubMed ID: 23323645
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]